Your current location:

KBI’s Latest Achievements in the Development of Imaging and Circulating Biomarkers for the Assessment of Hepatic Lesions in NHP Models of NASH Will Be Presented at AASLD Liver Meeting®2018

2018-10-23
21095
Kunming, China, October 23, 2018

Kunming Biomed International (KBI) has previously developed large cohorts of NASH and liver fibrosis models in nonhuman primates (NHPs) mirroring human patient’s disease pathophysiology, clinical progression, and histopathological stages, including steatosis monkeys (n>800), NASH monkeys (n>500) and liver fibrosis monkeys (n>150).


For the upcoming Liver Meeting® 2018 of American Association for the Study of Liver Diseases (AASLD), KBI will present its accomplishments in the development and validation of non-invasive imaging biomarkers such as PDFF and MRI-ECV as well as circulating biomarkers like TIMP-1 for the assessment of hepatic lesions in our NHP model of Nonalcoholic Steatohepatitis (NASH).


Join KBI and more than 9,500 hepatologists and hepatology health professionals from around the world at the annual AASLD conference to be held at the Moscone North and South Convention Center in San Francisco, California on 9-13 November 2018.


Our poster presentation details are below:
    Publication Number: 1767
    Session Date and Time: Sunday, November 11, 2018, 8:00 AM
    Presentation Type: Poster Presentation
    Location: Moscone Center North/South Building, Hall C

Contact us if you need more information.

Copyright © 2024 Kunming Biomed International Ltd. All Rights Reserved     |Privacy Policy|Terms of Use|
4571 Boda Road, Chenggong, Kunming, Yunnan, 650500, China